Sign up
Log in
MARKET
RNAC
RNAC
Cartesian
NASDAQ
17.49
+0.91
+5.49%
After Hours: 17.49 0 0.00% 16:01 07/26 EDT
OPEN
16.96
PREV CLOSE
16.58
HIGH
17.76
LOW
16.22
VOLUME
54.69K
TURNOVER
0
52 WEEK HIGH
42.60
52 WEEK LOW
11.67
MARKET CAP
373.93M
P/E (TTM)
-0.3642
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RNAC last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at RNAC last week (0708-0712)?
Weekly Report · 07/15 10:39
argenx SE: A Post FDA Approval Assessment
Seeking Alpha · 07/10 16:19
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics, Inc. Is a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases. The company issued to new employees options to purchase an aggregate of 35,198 shares of the Company’s common stock. The options vest on July 1, 2024.
Barchart · 07/08 15:05
Weekly Report: what happened at RNAC last week (0701-0705)?
Weekly Report · 07/08 10:41
Cartesian Therapeutics Price Target Maintained With a $42.00/Share by Needham
Dow Jones · 07/08 09:47
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $42 Price Target
Benzinga · 07/08 09:37
Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of NIO Inc. Fell 8.5% to $4.4550 on Friday. The company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family reasons. Qualigen Therapeutics, Inc. Shares jumped 120% in today's mid-day session. Macy's, Macy's and Zoomcar Holdings were among the other stocks moving in Friday's session.
Benzinga · 07/05 16:59
About RNAC
Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Webull offers Cartesian Therapeutics Inc stock information, including NASDAQ: RNAC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNAC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading RNAC stock methods without spending real money on the virtual paper trading platform.